SCHEMBL5066732

SCHEMBL5066732

Cc1cc2nccc(C)n2n1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.59
KMT2A Q03164 2/20 0.59
HTT P42858 1/20 0.59
POLB P06746 2/20 0.56
NPC1 O15118 4/20 0.51
L3MBTL1 Q9Y468 1/20 0.43
CYP1A2 P05177 1/20 0.42
RAB9A P51151 3/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
TP53 P04637 1/20 0.41
HPGD P15428 1/20 0.41
PKM P14618 1/20 0.38
AURKA O14965 1/20 0.37
UHRF1 Q96T88 1/20 0.37
CCR1 P32246 1/20 0.37
CCR5 P51681 1/20 0.37
CCR8 P51685 1/20 0.37
PIK3CG P48736 1/20 0.36
KDM4E B2RXH2 3/20 0.36
ALDH1A1 P00352 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18030277 0.80 HTT (0.40) MEN1KMT2AHTTPOLBNPC1
SCHEMBL12789272 0.80 MEN1 (0.60) MEN1KMT2AHTTPOLBNPC1
SCHEMBL12789269 0.80 NPC1 (0.56) MEN1KMT2AHTTPOLBNPC1
SCHEMBL7465807 0.80 MEN1 (0.56) MEN1KMT2AHTTPOLBNPC1
SCHEMBL26817132 0.80 PIK3CG (0.55) MEN1KMT2AHTTPOLBNPC1
Hydrochloric Acid SCHEMBL8149596 0.79 MEN1 (0.54) MEN1KMT2AHTTPOLBNPC1
SCHEMBL22520937 0.77 KMT2A (0.53) MEN1KMT2AHTTPOLBNPC1
SCHEMBL16705094 0.76 HTT (0.37) MEN1KMT2AHTTPOLBNPC1
SCHEMBL16421204 0.74 KDM4E (0.50) MEN1KMT2AHTTPOLBNPC1
SCHEMBL30786501 0.74 HTT (0.54) MEN1KMT2AHTTPOLBNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1067894-A4 PROTEASE INHIBITORS SMITHKLINE BEECHAM CORP (US) 2004-09-08 EP claimed
US-6518267-B1 Protease inhibitors SMITHKLINE BEECHAM CORPORATION 2003-02-11 US claimed
EP-1067894-A2 PROTEASE INHIBITORS SmithKline Beecham Corporation (US) 2001-01-17 EP claimed
WO-1999059526-A2 PROTEASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 1999-11-25 WO claimed
US-20250353841-A1 HETEROCYCLIC COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE HUFF SARAH ELIZABETH (US) 2025-11-20 US disclosed
EP-4422589-A2 COMPOSITION COMPRISING THE COMBINATION OF TWO PARTICULAR OXIDATION DYEING PRECURSORS, AN AMPHOTERIC OR ZWITTERIONIC SURFACTANT AND A SOLID FATTY SUBSTANCE L'OREAL (FR) 2024-09-04 EP disclosed
WO-2023073131-A2 COMPOSITION COMPRISING THE COMBINATION OF TWO PARTICULAR OXIDATION DYEING PRECURSORS, AN AMPHOTERIC OR ZWITTERIONIC SURFACTANT AND A SOLID FATTY SUBSTANCE L'OREAL (FR) 2023-05-04 WO disclosed
US-20170204073-A1 COMPOUNDS FOR NONSENSE SUPPRESSION, AND METHODS FOR THEIR USE PTC THERAPEUTICS, INC. (US) 2017-07-20 US disclosed
US-9611230-B2 1,3,4-oxadiazole benzoic acid compounds and their use for nonsense suppression and the treatment of disease PTC THERAPEUTICS, INC. (US) 2017-04-04 US disclosed
US-7345180-B2 Compound inhibiting dipeptidyl peptidase IV SANWA KAGAKU KENKYUSHO CO., LTD. (JP) 2008-03-18 US disclosed
US-20060229286-A1 Compound inhibiting dipeptidyl peptidase IV SANWA KAGAKU KENKYUSHO CO., LTD. (JP) 2006-10-12 US disclosed
EP-1067894-A4 PROTEASE INHIBITORS SMITHKLINE BEECHAM CORP (US) 2004-09-08 EP disclosed
US-6518267-B1 Protease inhibitors SMITHKLINE BEECHAM CORPORATION 2003-02-11 US disclosed
EP-1067894-A2 PROTEASE INHIBITORS SmithKline Beecham Corporation (US) 2001-01-17 EP disclosed
WO-1999059526-A2 PROTEASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 1999-11-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250353841-A1 HETEROCYCLIC COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE HTT, HYPK, ATXN2 MEN1 2821/4885KMT2A 171/4885HTT 1/4885
US-20170204073-A1 COMPOUNDS FOR NONSENSE SUPPRESSION, AND METHODS FOR THEIR USE NSUN2, UPF1, NSUN3 MEN1 2836/4885KMT2A 1404/4885HTT 78/4885
US-20060229286-A1 Compound inhibiting dipeptidyl peptidase IV DPP4, DPP3, DPP7 MEN1 2434/4885KMT2A 3192/4885HTT 2749/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.